Androgen deficiency in the aging male: Benefits and risks of androgen supplementation

Journal of Steroid Biochemistry and Molecular Biology

Volumn 85, Issue 2-5, 2003, Pages 349-355

  Gooren, Louis ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aging; Bone; Muscle; Prostate disease; Psyche; Testosterone

Indexed keywords

ANDROGEN; ATAMESTANE; FINASTERIDE; TESTOSTERONE;

AGING; ANDROGEN BLOOD LEVEL; ANDROGEN DEFICIENCY; BODY MASS; BONE; BONE DENSITY; BONE MASS; BRAIN FUNCTION; CANCER RISK; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; GYNECOMASTIA; HEMATOPOIESIS; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LIPID STORAGE; MALE; MUSCLE FUNCTION; MUSCLE STRENGTH; PATHOPHYSIOLOGY; PREDICTION; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; SEXUAL FUNCTION; SLEEP APNEA SYNDROME; SUPPLEMENTATION; TESTOSTERONE BLOOD LEVEL; VISCERA;

EID: 0042388613     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00206-1     Document Type: Conference Paper

References (64)

1. Kaufman J.M., Vermeulen A. Declining gonadal function in elderly men. Baillieres Clin. Endocrinol. Metab. 11:1997;289-309.
2. Gray A., Feldman H.A., McKinlay J.B., Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 73:1991;1016-1025.
3. Vermeulen A., Kaufman J.M., Giagulli V.A. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J. Clin. Endocrinol. Metab. 81:1996;1821-1826.
4. Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86:2001;724-731.
5. Morley J.E., Kaiser F.E., Perry H.M. III, Patrick P., Morley P.M., Stauber P.M., Vellas B., Baumgartner R.N., Garry P.J. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 46:1997;410-413.
6. Orwoll E.S., Klein R.F. Osteoporosis in men. Endocr. Rev. 16:1995;87-116.
7. Jones G., Nguyen T., Sambrook P., Kelly P.J., Eisman J.A. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ. 309:1994;691-695.
8. Pfeilschifter J., Scheidt-Nave C., Leidig-Bruckner G., Woitge H.W., Blum W.F., Wuster C., Haack D., Ziegler R. Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50- to 80-year-old men and women. J. Clin. Endocrinol. Metab. 81:1996;2534-2540.
9. Finkelstein J.S., Neer R.M., Biller B.M., Crawford J.D., Klibanski A. Osteopenia in men with a history of delayed puberty. N. Engl. J. Med. 326:1992;600-604.
10. Katznelson L., Finkelstein J.S., Schoenfeld D.A., Rosenthal D.I., Anderson E.J., Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. 81:1996;4358-4365.
11. Morley J.E., Perry H.M. III, Kaiser F.E., Kraenzle D., Jensen J., Houston K., Mattammal M., Perry H.M. Jr. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J. Am. Geriatr. Soc. 41:1993;149-152.
12. Tenover J.S. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 75:1992;1092-1098.
13. Snyder P.J., Peachey H., Hannoush P., Berlin J.A., Loh L., Lenrow D.A., Holmes J.H., Dlewati A., Santanna J., Rosen C.J., Strom B.L. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. 84:1999;2647-2653.
14. Faustini-Fustini M., Rochira V., Carani C. Oestrogen deficiency in men: where are we today? Eur. J. Endocrinol. 140:1999;111-129.
15. Rudman D., Drinka P.J., Wilson C.R., Mattson D.E., Scherman F., Cuisinier M.C., Schultz S. Relations of endogenous anabolic hormones and physical activity to bone mineral density and lean body mass in elderly men. Clin. Endocrinol. (Oxford). 40:1994;653-661.
16. Bross R., Javanbakht M., Bhasin S. Anabolic interventions for aging-associated sarcopenia. J. Clin. Endocrinol. Metab. 84:1999;3420-3430.
17. K.S. Nair, Muscle protein turnover: methodological issues and the effect of aging, J. Gerontol. A Biol. Sci. Med. Sci. 50 (1995) 107-112.
18. Baumgartner R.N., Waters D.L., Gallagher D., Morley J.E., Garry P.J. Predictors of skeletal muscle mass in elderly men and women. Mech. Ageing Dev. 107:1999;123-136.
19. Sih R., Morley J.E., Kaiser F.E., Perry H.M. III, Patrick P., Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. 82:1997;1661-1667.
20. Urban R.J., Bodenburg Y.H., Gilkison C., Foxworth J., Coggan A.R., Wolfe R.R., Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am. J. Physiol. 269:1995;E820-E826.
21. Clague J.E., Wu F.C., Horan M.A. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int. J. Androl. 22:1999;261-265.
22. Janowsky J.S., Oviatt S.K., Orwoll E.S. Testosterone influences spatial cognition in older men. Behav. Neurosci. 108:1994;325-332.
23. Barrett-Connor E., Goodman-Gruen D., Patay B. Endogenous sex hormones and cognitive function in older men. J. Clin. Endocrinol. Metab. 84:1999;3681-3685.
24. Seidman S.N., Walsh B.T. Testosterone and depression in aging men. Am. J. Geriatr. Psychiatr. 7:1999;18-33.
25. Araujo A.B., Durante R., Feldman H.A., Goldstein I., McKinlay J.B. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom. Med. 60:1998;458-465.
26. L.J.G. Gooren, Gynecomastia, in: J.A.H. Wass, Shalet S.M. (Eds.), Oxford Textbook of Endocrinology and Diabetes, Oxford University press, Oxford, UK, 2002.
27. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 117:1992;807-811.
28. Swartz C.M., Young M.A. Low serum testosterone and myocardial infarction in geriatric male inpatients. J. Am. Geriatr. Soc. 35:1987;39-44.
29. Vermeulen A., Kaufman J.M. Androgens and cardiovascular disease in men and women. Aging Male. 1:1998;35-50.
30. Kannel W.B., Cupples L.A., Ramaswami R., Stokes J. III, Kreger B.E., Higgins M. Regional obesity and risk of cardiovascular disease; the Framingham Study. J. Clin. Epidemiol. 44:1991;183-190.
31. Despres J.P., Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr. Opin. Lipidol. 5:1994;274-289.
32. Bjorntorp P. Regional obesity and NIDDM. Adv. Exp. Med. Biol. 334:1993;279-285.
33. Marin P., Arver S. Androgens and abdominal obesity. Baillieres Clin. Endocrinol. Metab. 12:1998;441-451.
34. Seidell J.C., Bjorntorp P., Sjostrom L., Kvist H., Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 39:1990;897-901.
35. Tchernof A., Labrie F., Belanger A., Prud'homme D., Bouchard C., Tremblay A., Nadeau A., Despres J.P. Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis. 133:1997;235-244.
36. Simon D., Charles M.A., Nahoul K., Orssaud G., Kremski J., Hully V., Joubert E., Papoz L., Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J. Clin. Endocrinol. Metab. 82:1997;682-685.
37. Matsumoto A.M., Sandblom R.E., Schoene R.B., Lee K.A., Giblin E.C., Pierson D.J., Bremner W.J. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin. Endocrinol. (Oxford). 22:1985;713-721.
38. Shahidi N.T. Androgens and erythropoiesis. N. Engl. J. Med. 289:1973;72-80.
39. Hajjar R.R., Kaiser F.E., Morley J.E. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J. Clin. Endocrinol. Metab. 82:1997;3793-3796.
40. Jockenhovel F., Vogel E., Reinhardt W., Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur. J. Med. Res. 2:1997;293-298.
41. Grunstein R.R., Handelsman D.J., Lawrence S.J., Blackwell C., Caterson I.D., Sullivan C.E. Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy. J. Clin. Endocrinol. Metab. 68:1989;352-358.
42. Santamaria J.D., Prior J.C., Fleetham J.A. Reversible reproductive dysfunction in men with obstructive sleep apnoea. Clin. Endocrinol. (Oxford). 28:1988;461-470.
43. Sandblom R.E., Matsumoto A.M., Schoene R.B., Lee K.A., Giblin E.C., Bremner W.J., Pierson D.J. Obstructive sleep apnea syndrome induced by testosterone administration. N. Engl. J. Med. 308:1983;508-510.
44. Schneider B.K., Pickett C.K., Zwillich C.W., Weil J.V., McDermott M.T., Santen R.J., Varano L.A., White D.P. Influence of testosterone on breathing during sleep. J. Appl. Physiol. 61:1986;618-623.
45. Stewart D.A., Grunstein R.R., Berthon-Jones M., Handelsman D.J., Sullivan C.E. Androgen blockade does not affect sleep-disordered breathing or chemosensitivity in men with obstructive sleep apnea. Am. Rev. Respir. Dis. 146:1992;1389-1393.
46. Marcelli M., Cunningham G.R. Hormonal signaling in prostatic hyperplasia and neoplasia. J. Clin. Endocrinol. Metab. 84:1999;3463-3468.
47. Sakr W.A., Grignon D.J., Crissman J.D., Heilbrun L.K., Cassin B.J., Pontes J.J., Haas G.P. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 8:1994;439-443.
48. Gormley G.J., Stoner E., Bruskewitz R.C., Imperato-McGinley J., Walsh P.C., McConnell J.D., Andriole G.L., Geller J., Bracken B.R., Tenover J.S., Vaughan E.D., Pappas F., Taylor A., Binkowitz B., Ng J. The effect of finasteride in men with benign prostatic hyperplasia (1992). J. Urol. 167:2002;1102-1107.
49. Hammond G.L., Kontturi M., Vihko P., Vihko R. Serum steroids in normal males and patients with prostatic diseases. Clin. Endocrinol. (Oxford). 9:1978;113-121.
50. Gann P.H., Hennekens C.H., Longcope C., Verhoek-Oftedahl W., Grodstein F., Stampfer M.J. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 26:1995;40-49.
51. Krieg M., Nass R., Tunn S. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J. Clin. Endocrinol. Metab. 77:1993;375-381.
52. Yeh S., Miyamoto H., Shima H., Chang C. From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc. Natl. Acad. Sci. U.S.A. 95:1998;5527-5532.
53. Schweikert H.U., Tunn U.W., Habenicht U.F., Arnold J., Senge T., Schulze H., Schroder F.H., Blom J.H., Ennemoser O., Horniger W. Effects of estrogen deprivation on human benign prostatic hyperplasia. J. Steroid Biochem. Mol. Biol. 44:1993;573-576.
54. Radlmaier A., Eickenberg H.U., Fletcher M.S., Fourcade R.O., Reis Santos J.M., van Aubel O.G., Bono A.V. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate. 29:1996;199-208.
55. Schatzl G., Reiter W.J., Thurridl T., Waldmuller J., Roden M., Soregi S., Madersbacher S. Endocrine patterns in patients with benign and malignant prostatic diseases. Prostate. 44:2000;219-224.
56. Kleinman K.J.P., McKinlay J.B. Prostate cancer: how much do we know and how do we know it? Aging Male. 3:2000;115-123.
57. Carter H.B., Pearson J.D., Metter E.J., Chan D.W., Andres R., Fozard J.L., Rosner W., Walsh P.C. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate. 27:1995;25-31.
58. Behre H.M., Bohmeyer J., Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin. Endocrinol. (Oxford). 40:1994;341-349.
59. Sasagawa I., Nakada T., Kazama T., Satomi S., Terada T., Katayama T. Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy. Int. Urol. Nephrol. 22:1990;279-284.
60. Wallace E.M., Pye S.D., Wild S.R., Wu F.C. Prostate-specific antigen and prostate gland size in men receiving exogenous testosterone for male contraception. Int. J. Androl. 16:1993;35-40.
61. Holmang S., Marin P., Lindstedt G., Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate. 23:1993;99-106.
62. Sundaram K., Kumar N., Bardin C.W. 7 alpha-methyl-nortestosterone (MENT): the optimal androgen for male contraception. Ann. Med. 25:1993;199-205.
63. P.J. Snyder, Development of criteria to monitor the occurrence of prostate cancer in testosterone clinical trials, in: S. Bhasin, H.L. Gabelnick, R.S. Swerdloff, C. Wang (Eds.), Pharmacology, Biology, and Clinical Applications of Androgens, Wiley, New York, 1996, pp. 143-150.
64. Morales A. Andropause, androgen therapy and prostate safety. Aging Male. 2:1999;81-87.